F. Ann Millner - Nov 15, 2024 Form 4 Insider Report for MERIT MEDICAL SYSTEMS INC (MMSI)

Role
Director
Signature
/s/ Brian G. Lloyd, Attorney-in-Fact
Stock symbol
MMSI
Transactions as of
Nov 15, 2024
Transactions value $
-$638,125
Form type
4
Date filed
11/18/2024, 03:59 PM
Previous filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MMSI Common Stock, No Par Value Options Exercise $631K +12.5K +38.59% $50.50 44.9K Nov 15, 2024 Direct F1
transaction MMSI Common Stock, No Par Value Sale -$1.27M -12.5K -27.85% $101.55 32.4K Nov 15, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MMSI Non-qualified stock options (right to buy) Options Exercise $0 -12.5K -100% $0.00 0 Nov 15, 2024 Common Stock 12.5K $50.50 Direct F1, F3
holding MMSI Non-qualified stock options (right to buy) 13.8K Nov 15, 2024 Common Stock 13.8K $52.17 Direct F4
holding MMSI Non-qualified stock options (right to buy) 7.5K Nov 15, 2024 Common Stock 7.5K $52.17 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2023.
F2 The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.78 to $101.97, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F3 Becomes exercisable in equal annual installments of 20% commencing 06/07/2019.
F4 Becomes exercisable in equal annual installments of 33% commencing 05/24/2020.
F5 Becomes exercisable in equal annual installments of 33% commencing 05/31/2020.